Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $11.00.

Several equities research analysts have recently weighed in on the stock. Wall Street Zen cut shares of Evaxion A/S from a “buy” rating to a “hold” rating in a research report on Sunday, March 22nd. Lake Street Capital decreased their price objective on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, March 9th. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Evaxion A/S in a research report on Friday, April 24th. JonesTrading assumed coverage on shares of Evaxion A/S in a research report on Tuesday, March 10th. They set a “buy” rating and a $10.00 price objective for the company. Finally, Maxim Group began coverage on shares of Evaxion A/S in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 price objective for the company.

Evaxion A/S Trading Up 0.8%

EVAX opened at $3.64 on Friday. Evaxion A/S has a twelve month low of $2.07 and a twelve month high of $12.15. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.41. The company has a fifty day moving average of $4.05 and a 200-day moving average of $4.23. The stock has a market cap of $30.36 million, a PE ratio of -2.48 and a beta of 0.24.

Evaxion A/S (NASDAQ:EVAX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.43). On average, sell-side analysts predict that Evaxion A/S will post -0.5 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. bought a new position in Evaxion A/S in the fourth quarter worth approximately $38,000. Wesbanco Bank Inc. bought a new position in Evaxion A/S in the fourth quarter worth approximately $48,000. SmartHarvest Portfolios LLC bought a new position in Evaxion A/S in the fourth quarter worth approximately $72,000. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Evaxion A/S in the first quarter valued at $112,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Evaxion A/S during the first quarter valued at about $146,000. 11.04% of the stock is owned by institutional investors and hedge funds.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.